Desmopressin acetate is a structural analogue of natural arginine vasopressin. Intravenous or subcutaneous administration of 0.3ug/kg body weight can increase the activity of coagulation factor VIII (VIII: C) in plasma by 2-4 times, increase the content of Von Willebrand factor antigen (VWF: AG), and release tissue plasminogen activator (t-PA). The bioavailability of subcutaneous injection is about 85% of the bioavailability of intravenous injection. The maximum blood concentration of 0.3ug/kg body weight reaches a peak about 60 minutes after administration, with an average value of about 600pg/ml. The plasma half-life is 3-4 hours, and the hemostatic effect depends on the half-life of VIII: C in plasma, which is about 8-12 hours. It can shorten the bleeding time of patients with uremia, cirrhosis, congenital or drug-induced platelet dysfunction, etc. Use in patients with type IIB von Willebrand disease may cause platelet aggregation or thrombocytopenia. Use can avoid the risk of HIV or hepatitis virus transmission caused by the use of factor VIII concentrate.

It has a similar structure to the natural hormone arginine vasopressin, but after structural modification, its action time is prolonged and there is no pressor side effect; intravenous injection of 0.3 micrograms per kilogram of body weight can increase the activity of coagulation factor VIII in plasma by 2-4 times, while increasing von Willebrand antigen factor and releasing tissue plasminogen activator; it can be used to shorten or normalize bleeding time; and avoid the risk of HIV and hepatitis virus infection caused by the use of factor XII preparations.

This product is a guanine nucleoside analogue that has an inhibitory effect on hepatitis B virus (HBV) polymerase. It is phosphorylated to become an active triphosphate, inhibiting the initiation of viral polymerase (reverse transcriptase), the formation of the reverse transcription negative strand of pregenomic mRNA, and the synthesis of the positive strand of HBV DNA.